FR 190809
Latest Information Update: 18 Jul 2002
Price :
$50 *
At a glance
- Originator Fujisawa
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 01 Jun 1999 New profile
- 01 Jun 1999 Preclinical development for Hypercholesterolaemia in Japan (Unknown route)